Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLRBNASDAQ:GNPXOTCMKTS:PVCTNASDAQ:RGLSNASDAQ:ZSAN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLRBCellectar Biosciences$4.95-30.4%$8.88$4.47▼$94.50$8.97M0.52140,443 shs810,421 shsGNPXGenprex$0.24+4.9%$0.28$0.20▼$3.97$6.71M-0.414.13 million shs1.46 million shsPVCTProvectus Biopharmaceuticals$0.08+0.1%$0.08$0.04▼$0.15$31.52M0.78200,667 shs222,733 shsRGLSRegulus Therapeutics$8.16$7.39$0.83▼$8.35$564.92M0.35981,243 shsN/AZSANZosano Pharma$0.00$3.90$0.46▼$37.45$1K3.3425,375 shs5,685 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLRBCellectar Biosciences-10.00%-20.42%-5.58%-18.84%-90.52%GNPXGenprex+3.59%-0.48%-35.80%-0.96%-87.91%PVCTProvectus Biopharmaceuticals-0.13%-3.97%-11.99%-25.03%-40.60%RGLSRegulus Therapeutics0.00%+0.25%+2.90%+366.29%+357.14%ZSANZosano Pharma0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLRBCellectar Biosciences3.0939 of 5 stars3.25.00.00.03.00.01.3GNPXGenprex1.6836 of 5 stars0.04.00.04.72.20.00.6PVCTProvectus BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ARGLSRegulus Therapeutics2.219 of 5 stars2.15.00.00.02.33.30.0ZSANZosano PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLRBCellectar Biosciences 2.33Hold$375.007,475.76% UpsideGNPXGenprex 0.00N/AN/AN/APVCTProvectus Biopharmaceuticals 0.00N/AN/AN/ARGLSRegulus Therapeutics 2.29Hold$8.504.17% UpsideZSANZosano Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CLRB, RGLS, GNPX, ZSAN, and PVCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025CLRBCellectar BiosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/1/2025RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$9.004/30/2025RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/30/2025RGLSRegulus TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/30/2025RGLSRegulus TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$7.004/30/2025RGLSRegulus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$28.00 ➝ $11.004/30/2025RGLSRegulus TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$8.00 ➝ $7.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLRBCellectar BiosciencesN/AN/AN/AN/A$8.98 per shareN/AGNPXGenprexN/AN/AN/AN/A$0.15 per shareN/APVCTProvectus Biopharmaceuticals$620K50.84N/AN/A($0.01) per share-7.50RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.17 per shareN/AZSANZosano Pharma$790K0.00N/AN/A$9.74 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLRBCellectar Biosciences-$44.58M-$21.92N/AN/AN/AN/A-619.70%-158.04%8/11/2025 (Estimated)GNPXGenprex-$21.11MN/A0.00N/AN/AN/A-664.65%-370.18%8/8/2025 (Estimated)PVCTProvectus Biopharmaceuticals-$4.76MN/A0.00∞N/A-815.81%N/A-644.80%8/11/2025 (Estimated)RGLSRegulus Therapeutics-$46.36M-$0.73N/AN/AN/AN/A-57.53%-53.26%8/6/2025 (Estimated)ZSANZosano Pharma-$29.92M-$14.50N/A∞N/A-8,375.11%-177.06%-119.14%N/ALatest CLRB, RGLS, GNPX, ZSAN, and PVCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CLRBCellectar Biosciences-$5.10-$3.90+$1.20-$0.14N/AN/A5/12/2025Q1 2025GNPXGenprex-$0.82-$0.26+$0.56-$0.26N/AN/A5/8/2025Q1 2025RGLSRegulus Therapeutics-$0.29-$0.15+$0.14-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLRBCellectar BiosciencesN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/APVCTProvectus BiopharmaceuticalsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/AZSANZosano PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLRBCellectar BiosciencesN/A2.472.47GNPXGenprexN/A1.941.94PVCTProvectus BiopharmaceuticalsN/A0.110.11RGLSRegulus TherapeuticsN/A16.3116.31ZSANZosano PharmaN/A1.611.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLRBCellectar Biosciences16.41%GNPXGenprex14.05%PVCTProvectus Biopharmaceuticals0.05%RGLSRegulus Therapeutics92.38%ZSANZosano PharmaN/AInsider OwnershipCompanyInsider OwnershipCLRBCellectar Biosciences5.04%GNPXGenprex8.47%PVCTProvectus Biopharmaceuticals14.70%RGLSRegulus Therapeutics4.35%ZSANZosano Pharma2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLRBCellectar Biosciences101.81 million1.72 millionOptionableGNPXGenprex2027.82 million25.47 millionNo DataPVCTProvectus Biopharmaceuticals4420.28 million366.48 millionNot OptionableRGLSRegulus Therapeutics3069.23 million66.22 millionOptionableZSANZosano Pharma404.90 million4.78 millionNot OptionableCLRB, RGLS, GNPX, ZSAN, and PVCT HeadlinesRecent News About These CompaniesMicroneedles for Drug Delivery Patent Landscape Report and Forecast 2024-2032, Featuring Minnesota Mining and Manufacturing, BD and Co, Zosano Pharma, Raphas, Nano, and Pass TechnologiesMarch 7, 2025 | globenewswire.comNifty PharmaAugust 2, 2024 | economictimes.indiatimes.comThe seven steps to selling in pharmaJuly 31, 2024 | pharmaphorum.comPAktuelle Empfehlungen zur ZOSANOJuly 28, 2024 | finanznachrichten.deHOOK HOOKIPA Pharma Inc.April 12, 2024 | seekingalpha.comNachrichten - Weitere NachrichtenJanuary 9, 2024 | wallstreet-online.deWLISTEN: Supreme Court hears arguments on legality of Purdue Pharma bankruptcy planDecember 6, 2023 | pbs.orgPDer Börsen-Tag: Diese US-Aktie stürzte nachbörslich abAugust 22, 2023 | n-tv.deNEast Bay Business NewsMay 18, 2023 | bizjournals.comMankind Pharma IPO opens on April 25, listing scheduled for May 9April 27, 2023 | moneycontrol.comAstellas PharmaApril 6, 2023 | forbes.comGiiant Pharma Receives Financial Support From the US Crohn’s and Colitis FoundationFebruary 5, 2023 | finance.yahoo.comFTC asks court to hold 'pharma bro' Martin Shkreli in contempt for failing to abide by ordersJanuary 23, 2023 | washingtonexaminer.comWZosano Pharma Corporation (ZSANQ)November 5, 2022 | ca.finance.yahoo.comNow bankrupt, Zosano sells off its drug delivery tech that once enticed Novo Nordisk, Eli LillyOctober 13, 2022 | endpts.comEBankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma GiantsOctober 12, 2022 | msn.comBankrupt Zosano Pharma Says Unsecured Creditors Will Recoup 28% of ClaimsAugust 28, 2022 | marketwatch.comEast Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 millionAugust 27, 2022 | bizjournals.comZosano Pharma Corp (ZSANQ)August 24, 2022 | investing.comEast Bay company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1MJuly 26, 2022 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLRB, RGLS, GNPX, ZSAN, and PVCT Company DescriptionsCellectar Biosciences NASDAQ:CLRB$4.95 -2.16 (-30.38%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Genprex NASDAQ:GNPX$0.24 +0.01 (+4.87%) As of 03:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Provectus Biopharmaceuticals OTCMKTS:PVCT$0.08 +0.00 (+0.13%) As of 03:07 PM EasternProvectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.Regulus Therapeutics NASDAQ:RGLS$8.16 0.00 (0.00%) As of 06/25/2025Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Zosano Pharma NASDAQ:ZSANZosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
